NH TherAguix Nanodrugs for theranostic Géraldine LE

NH TherAguix
Nanodrugs for theranostic
Géraldine LE DUC, PhD, CEO
[e-mail]
Olivier TILLEMENT, PhD, CSO
[e-mail]
NH TherAguix – Tous droits réservés

•Nearly 2/3 of cancer patients will receive radiation therapy during their illness.
•Escalation of radiation dose is an approach to overall survival of patients.
Some radiation resistant or badly positioned tumours remain not addressed.
Brain, lung, pancreatic, head and neck, cervical and prostate
•Our technology improves anti-tumour efficacy while reducing side effects in
normal tissues
10%-20% of all cancer patients would benefit from our nanomedicine
The context
More sensitive for solid tumors, less destructive for surrounding tissues
NH TherAguix – Tous droits réservés

The AGuIX technology
See what you target, target what you see
MR imaging
Combination
Diagnostic/Therapeutics
Theranostics
Radiation therapy
Contrast agent
AND
Radiosensitizer
NH TherAguix – All rights reserved
Intravenous injection
Unique administration

The project
Projects currently in progress with AGuIX
NH TherAguix – All rights reserved
Priority programs
Brain tumors
(GBM, metas)
In vitro Phase 1
Ongoing Collaborations
Pancreas
Lung
Uterus
Prostate
Head&Neck
In vivo
1000 vials available, first ‘in man’ foreseen at spring 2016, 2 clinical trials

Collaborations
NH TherAguix – Tous droits réservés
Enlarging and deepening the knowledge (refining):
• Radiobiology
• Biodistribution within the tissues (nucleus, interstitium)
• Analytical Chemistry
• Other applications :
Imaging, RPE